Novo Nordisk bets on RNA in several business areas

It is not just vaccine companies that see potential in using RNA technologies – Novo Nordisk also has agreements in place for the therapies.

Photo: Novo Nordisk/ PR

When Novo Nordisk entered into an agreement with US company Dicerna two years ago, it had seen the potential in manipulating RNA, like many other players in the industry.

Danish financial daily Børsen reports that the deal concerns a specific form of RNA technology, called RNA interference, or RNAi, which aims to reduce the production of damaging proteins. Karin Conde-Knape, Senior Vice President of Global Drug Discovery at Novo Nordisk, calls the approach "clearly exciting".

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs